Home LiteratureArticle Details
PMID: 4114458 Published · ppublish English Clinical Trial Journal Article

Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Zeitschrift fur Neurologie ·Vol. 202 ·No. 1 ·1972-00-00 ·Pages 1-20

Rinne UK, Sonninen V, Sirtola T

Abstract

暂无摘要

MeSH Terms
Biopsy Carboxy-Lyases/antagonists & inhibitors Clinical Trials as Topic Dihydroxyphenylalanine/administration & dosage,adverse effects,blood,therapeutic use Drug Combinations Drug Synergism Female Humans Hydroxyindoleacetic Acid/cerebrospinal fluid Liver/pathology Male Middle Aged Nausea/chemically induced Parkinson Disease/blood,cerebrospinal fluid,drug therapy,pathology Time Factors Vanilmandelic Acid/cerebrospinal fluid Vomiting/chemically induced
Chemicals
Drug Combinations Hydroxyindoleacetic Acid Vanilmandelic Acid Dihydroxyphenylalanine Carboxy-Lyases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Rinne U K
Sonninen V
Sirtola T
References (51)
51 references, click to expand
  1. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Dtsch Z Nervenheilkd. 1970;197(1):85-100 PMID: 5522871
  2. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Trans Am Neurol Assoc. 1968;93:56-63 PMID: 4885744
  3. Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain.
    Experientia. 1968 Feb 15;24(2):130-1 PMID: 5643797
  4. [The capillary enzyme barrier for DOPA at the level of some brain stem nuclei in the rat].
    Experientia. 1970 Apr 15;26(4):381-3 PMID: 5439606
  5. Dopamine (3-hydroxytyramine) and brain function.
    Pharmacol Rev. 1966 Jun;18(2):925-64 PMID: 5328389
  6. L-dihydroxyphenylalanine: effect on S-adenosylmethionine in brain.
    Science. 1970 Jul 24;169(3943):395-7 PMID: 5450377
  7. The metabolism of orally administered L-Dopa in Parkinsonism.
    Br J Pharmacol. 1969 Sep;37(1):57-68 PMID: 5343357
  8. Further studies on tryptophan hydroxylase in rat brainstem and beef pineal.
    Biochem Pharmacol. 1969 May;18(5):1071-81 PMID: 5789774
  9. Treatment of parkinsonism with levodopa.
    Arch Neurol. 1969 Oct;21(4):343-54 PMID: 5820999
  10. Treatment of parkinsonism with L-dopa (study of 105 patients).
    Dis Nerv Syst. 1969 Nov;30(11):737-46 PMID: 5359046
  11. L-dopa in idiopathic parkinsonism.
    Lancet. 1969 Nov 8;2(7628):973-6 PMID: 4186975
  12. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia].
    Wien Klin Wochenschr. 1961 Nov 10;73:787-8 PMID: 13869404
  13. Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation.
    Clin Pharmacol Ther. 1971 Mar-Apr;12(2):344-52 PMID: 5577483
  14. [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
    Wien Klin Wochenschr. 1969 Sep 26;81(39):677-9 PMID: 5344299
  15. Treatment of Parkinsonism with Laevo-dopa.
    Br Med J. 1970 Feb 7;1(5692):331-7 PMID: 4906702
  16. SPECIFIC ASSAYS OF SOME PHOSPHATASES IN SUBCELLULAR FRACTIONS OF SMALL INTESTINAL MUCOSA.
    Nature. 1965 Feb 20;205:799-800 PMID: 14292314
  17. The blood-brain barrier for L-dopa in the hypothalamus.
    J Neurol Sci. 1971 Jan;12(1):77-93 PMID: 5541357
  18. L-dopa therapy in parkinsonism: mechanism of action.
    Psychiatr Neurol Neurochir. 1971 Jul-Aug;74(4):331-3 PMID: 5146239
  19. L-dopa: disaggregation of brain polysomes and elevation of brain tryptophan.
    Science. 1971 Aug 27;173(3999):833-5 PMID: 5572175
  20. On the mode of action of L-dopa in Parkinson's disease.
    Biochem Med. 1970 Feb;3(4):321-5 PMID: 4943208
  21. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.
    Lancet. 1970 May 2;1(7653):908-11 PMID: 4191547
  22. Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition.
    Brain Res. 1969 Sep;15(1):233-42 PMID: 5807767
  23. A method for evaluating disability in patients with Parkinson's disease.
    J Nerv Ment Dis. 1961 Aug;133:143-7 PMID: 13876261
  24. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Wien Klin Wochenschr. 1971 Apr 2;83(13):221-7 PMID: 4254333
  25. Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
    Annu Rev Med. 1971;22:305-26 PMID: 4944422
  26. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.
    J Pharmacol Exp Ther. 1968 May;161(1):14-20 PMID: 5648492
  27. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].
    Klin Wochenschr. 1960 Dec 15;38:1236-9 PMID: 13726012
  28. [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)].
    Arch Psychiatr Nervenkr (1970). 1967 Aug 8;210(1):29-35 PMID: 4292871
  29. L-dopa in Parkinsonism and the influence of previous thalamotomy.
    Br Med J. 1971 Jan 2;1(5739):7-13 PMID: 4923653
  30. L-Dopa treatment in Parkinson's Disease.
    Eur Neurol. 1970;4(6):348-69 PMID: 4932969
  31. Treatment of Parkinson's syndrome with L-dopa. A double blind study.
    Acta Neurol Scand. 1966;42(3):367-72 PMID: 5327616
  32. [Treatment of parkinsonism with L-Dopa associated with decarboxylase inhibitors. II].
    Rev Neurol (Paris). 1970 Nov;123(5):297-319 PMID: 5513630
  33. A double blind study of 1-dopa treatment in Parkinson's disease.
    Eur Neurol. 1968;1(3):180-91 PMID: 4880674
  34. Decrease of cerebral 5-hydroxytryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase.
    J Pharm Pharmacol. 1968 Mar;20(3):228-9 PMID: 4385052
  35. Effect of L-dopa on the hypothalamic, pineal and striatal monoamines and on the sexual behaviour of the rat.
    Brain Res. 1971 Jul 23;30(2):265-72 PMID: 5315473
  36. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Presse Med. 1969 Apr 5;77(17):619-22 PMID: 5785081
  37. Esterase, peptidase and proteinase activities of human cerebrospinal fluid in multiple sclerosis.
    Acta Neurol Scand. 1968;44(2):156-67 PMID: 5687877
  38. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase.
    Nature. 1967 Aug 19;215(5103):852-3 PMID: 6049735
  39. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Rev Neurol (Paris). 1970 Apr;122(4):243-8 PMID: 5472041
  40. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.
    Can Med Assoc J. 1969 Dec 27;101(13):59-68 PMID: 4903690
  41. Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase.
    Biochem Pharmacol. 1971 Jun;20(6):1243-7 PMID: 5315769
  42. Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease.
    Life Sci I. 1971 May 15;10(10):549-57 PMID: 5580101
  43. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Dtsch Med Wochenschr. 1969 Dec 26;94(52):2678-81 PMID: 4903342
  44. Drug-induced changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus.
    Br J Pharmacol Chemother. 1962 Aug;19:153-60 PMID: 13862807
  45. Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease.
    Mayo Clin Proc. 1970 Jun;45(6):438-43 PMID: 5425103
  46. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Neurology. 1970 Dec;20(12):36-40 PMID: 5533273
  47. On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method.
    Life Sci (1962). 1963 Jul;(7):448-58 PMID: 14012743
  48. Aromatic amino acids and modification of parkinsonism.
    N Engl J Med. 1967 Feb 16;276(7):374-9 PMID: 5334614
  49. Effects of L-dopa in Parkinson's disease.
    Lancet. 1969 Jul 26;2(7613):165-8 PMID: 4183130
  50. Proteinase activity of myelin.
    Brain Res. 1969 Oct;15(2):413-30 PMID: 5344375
  51. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).
    Ann Intern Med. 1970 Jan;72(1):29-35 PMID: 5410397
Article Info
Journal
Zeitschrift fur Neurologie
Abbr.
Z Neurol
ISSN
0012-1037
DOI
10.1007/BF00316422
Published
1972-00-00
Pages
1-20
Language
English
Region
Germany
NLM ID
0424070
Subset
IM
External Links
PubMed source DOI: 10.1007/BF00316422
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2